193 related articles for article (PubMed ID: 17938266)
1. Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses.
Guse K; Ranki T; Ala-Opas M; Bono P; Särkioja M; Rajecki M; Kanerva A; Hakkarainen T; Hemminki A
Mol Cancer Ther; 2007 Oct; 6(10):2728-36. PubMed ID: 17938266
[TBL] [Abstract][Full Text] [Related]
2. Noninvasive imaging for evaluation of the systemic delivery of capsid-modified adenoviruses in an orthotopic model of advanced lung cancer.
Sarkioja M; Kanerva A; Salo J; Kangasniemi L; Eriksson M; Raki M; Ranki T; Hakkarainen T; Hemminki A
Cancer; 2006 Oct; 107(7):1578-88. PubMed ID: 16948124
[TBL] [Abstract][Full Text] [Related]
3. A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer.
Ranki T; Kanerva A; Ristimäki A; Hakkarainen T; Särkioja M; Kangasniemi L; Raki M; Laakkonen P; Goodison S; Hemminki A
Gene Ther; 2007 Jan; 14(1):58-67. PubMed ID: 16900223
[TBL] [Abstract][Full Text] [Related]
4. Ad5/3-9HIF-Delta24-VEGFR-1-Ig, an infectivity enhanced, dual-targeted and antiangiogenic oncolytic adenovirus for kidney cancer treatment.
Guse K; Diaconu I; Rajecki M; Sloniecka M; Hakkarainen T; Ristimäki A; Kanerva A; Pesonen S; Hemminki A
Gene Ther; 2009 Aug; 16(8):1009-20. PubMed ID: 19440223
[TBL] [Abstract][Full Text] [Related]
5. Multimodal approach using oncolytic adenovirus, cetuximab, chemotherapy and radiotherapy in HNSCC low passage tumour cell cultures.
Dias JD; Guse K; Nokisalmi P; Eriksson M; Chen DT; Diaconu I; Tenhunen M; Liikanen I; Grénman R; Savontaus M; Pesonen S; Cerullo V; Hemminki A
Eur J Cancer; 2010 Feb; 46(3):625-35. PubMed ID: 20006487
[TBL] [Abstract][Full Text] [Related]
6. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
Wohlfahrt ME; Beard BC; Lieber A; Kiem HP
Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719
[TBL] [Abstract][Full Text] [Related]
7. Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy.
Lamfers ML; Grill J; Dirven CM; Van Beusechem VW; Geoerger B; Van Den Berg J; Alemany R; Fueyo J; Curiel DT; Vassal G; Pinedo HM; Vandertop WP; Gerritsen WR
Cancer Res; 2002 Oct; 62(20):5736-42. PubMed ID: 12384532
[TBL] [Abstract][Full Text] [Related]
8. Systemic efficacy of oncolytic adenoviruses in imagable orthotopic models of hormone refractory metastatic breast cancer.
Ranki T; Särkioja M; Hakkarainen T; von Smitten K; Kanerva A; Hemminki A
Int J Cancer; 2007 Jul; 121(1):165-74. PubMed ID: 17315187
[TBL] [Abstract][Full Text] [Related]
9. Treatment of prostate cancer with Ad5/3Delta24hCG allows non-invasive detection of the magnitude and persistence of virus replication in vivo.
Rajecki M; Kanerva A; Stenman UH; Tenhunen M; Kangasniemi L; Särkioja M; Ala-Opas MY; Alfthan H; Sankila A; Rintala E; Desmond RA; Hakkarainen T; Hemminki A
Mol Cancer Ther; 2007 Feb; 6(2):742-51. PubMed ID: 17308070
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer.
Raki M; Särkioja M; Desmond RA; Chen DT; Bützow R; Hemminki A; Kanerva A
Gynecol Oncol; 2008 Jan; 108(1):166-72. PubMed ID: 17950450
[TBL] [Abstract][Full Text] [Related]
11. Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus.
Raki M; Hakkarainen T; Bauerschmitz GJ; Särkioja M; Desmond RA; Kanerva A; Hemminki A
Gene Ther; 2007 Oct; 14(19):1380-8. PubMed ID: 17611584
[TBL] [Abstract][Full Text] [Related]
12. Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma.
Takagi-Kimura M; Yamano T; Tamamoto A; Okamura N; Okamura H; Hashimoto-Tamaoki T; Tagawa M; Kasahara N; Kubo S
Cancer Sci; 2013 Nov; 104(11):1433-9. PubMed ID: 23962292
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab increases viral distribution in human anaplastic thyroid carcinoma xenografts and enhances the effects of E1A-defective adenovirus dl922-947.
Libertini S; Iacuzzo I; Perruolo G; Scala S; Ieranò C; Franco R; Hallden G; Portella G
Clin Cancer Res; 2008 Oct; 14(20):6505-14. PubMed ID: 18927290
[TBL] [Abstract][Full Text] [Related]
14. Enhanced antitumor efficacy of a novel fiber chimeric oncolytic adenovirus expressing p53 on hepatocellular carcinoma.
Chen W; Wu Y; Liu W; Wang G; Wang X; Yang Y; Chen W; Tai Y; Lu M; Qian Q; Zhang Q; Chen G
Cancer Lett; 2011 Aug; 307(1):93-103. PubMed ID: 21504839
[TBL] [Abstract][Full Text] [Related]
15. Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors.
Hakkarainen T; Särkioja M; Lehenkari P; Miettinen S; Ylikomi T; Suuronen R; Desmond RA; Kanerva A; Hemminki A
Hum Gene Ther; 2007 Jul; 18(7):627-41. PubMed ID: 17604566
[TBL] [Abstract][Full Text] [Related]
16. Infectivity-enhanced adenoviruses deliver efficacy in clinical samples and orthotopic models of disseminated gastric cancer.
Kangasniemi L; Kiviluoto T; Kanerva A; Raki M; Ranki T; Sarkioja M; Wu H; Marini F; Höckerstedt K; Isoniemi H; Alfthan H; Stenman UH; Curiel DT; Hemminki A
Clin Cancer Res; 2006 May; 12(10):3137-44. PubMed ID: 16707613
[TBL] [Abstract][Full Text] [Related]
17. Noninvasive monitoring of mRFP1- and mCherry-labeled oncolytic adenoviruses in an orthotopic breast cancer model by spectral imaging.
Borovjagin AV; McNally LR; Wang M; Curiel DT; MacDougall MJ; Zinn KR
Mol Imaging; 2010 Apr; 9(2):59-75. PubMed ID: 20236604
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer.
Liikanen I; Tähtinen S; Guse K; Gutmann T; Savola P; Oksanen M; Kanerva A; Hemminki A
Mol Cancer Ther; 2016 Sep; 15(9):2259-69. PubMed ID: 27458139
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models.
Ganesh S; Gonzalez-Edick M; Gibbons D; Van Roey M; Jooss K
Clin Cancer Res; 2008 Jun; 14(12):3933-41. PubMed ID: 18559615
[TBL] [Abstract][Full Text] [Related]
20. Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans.
Bramante S; Kaufmann JK; Veckman V; Liikanen I; Nettelbeck DM; Hemminki O; Vassilev L; Cerullo V; Oksanen M; Heiskanen R; Joensuu T; Kanerva A; Pesonen S; Matikainen S; Vähä-Koskela M; Koski A; Hemminki A
Int J Cancer; 2015 Oct; 137(7):1775-83. PubMed ID: 25821063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
